FDA issues alert on potential dangers of unproven treatment for multiple sclerosis
date:May 11, 2012
omes.


The experimental procedure uses balloon angioplasty devices or stents to widen narrowed veins in the chest and neck. However, the FDA has learned of death, stroke, detachment and migration of the stents, damage to the treated vein, blood clots, cranial nerve damage and abdominal bleeding associated with the experimental procedure. Balloon angioplasty devices and stents have not been approved by the FDA for use in treating CCSVI.


MS is a progressive, immune-mediated disorder of the brai
3/6 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/03 12:33